LOS ANGELES--(BUSINESS WIRE)--Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that it will release results from its prospective, multi-center, pivotal clinical trial (NCT03112005) on the EyeArt® AI Eye Screening System for autonomous detection of diabetic retinopathy (DR) at the Association for Research in Vision and Ophthalmology (ARVO) Imaging in the Eye Conference this weekend in Vancouver, British Columbia.
- On behalf of the 15-center study team, Jennifer Lim, MD, Marion H. Schenk Chair in Ophthalmology and Director of Retina Service at the University of Illinois at Chicago, will present results from the EyeArt prospective, pivotal clinical trial “Artificial Intelligence Screening for Diabetic Retinopathy: Analysis From a Pivotal Multi-Center Prospective Clinical Trial.” The presentation will be part of the 2019 ARVO Imaging in the Eye Conference at 5:15 p.m. PDT on Saturday, April 27, 2019, in the Vancouver Convention Centre (East) Ballroom A and B.
-
In addition, the clinical team from the Washington University School
of Medicine (St. Louis) will present results from its independent
clinical study involving the EyeArt® AI Eye Screening
System in real-world clinical applications:
- “Cost-Effectiveness of Primary Care-Based Non-Mydriatic Fundus Photography with Automated Retinal Image Analysis Screening Among Low-Income Patients with Diabetes,” which will be presented at 11 a.m. PDT on Wednesday, May 1, 2019, in the Vancouver Convention Centre (West) Room 220.
- “Diabetic Retinopathy Screening in a Primary Care Setting Using Non-Mydriatic Photography and Automated Retinal Image Analysis Improves Compliance with Follow-Up Ophthalmic Care,” which will be Poster B0005 at 3 p.m. PDT on Wednesday, May 1, 2019, in the Vancouver Convention Centre West Exhibition Hall.
Eyenuk will showcase its EyeArt® AI Eye Screening System for autonomous detection of DR at Booth #1637 at the Vancouver Convention Centre Exhibition Hall. In addition, key management team members will be available to meet with researchers, clinicians and potential industry partners during the ARVO annual meeting.
About the EyeArt® AI Eye Screening System
The EyeArt AI Eye Screening System is the most extensively validated AI technology for autonomous detection of diabetic retinopathy, tested in the real world on more than half million patient visits globally with over two million images collected in real-world clinical environments. The EyeArt AI Eye Screening System makes in-clinic, real-time DR screening possible for any physician, enabling quick and accurate identification of patients with referable DR during a diabetic patient’s regular exam.
The EyeArt AI Eye Screening System was developed with funding in part from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). The EyeArt System has CE marking in the European Union and a Health Canada license. In the U.S., the EyeArt System is limited by federal law to investigational use.
VIDEO: Learn more about the EyeArt AI Eye Screening System for Diabetic Retinopathy
About Eyenuk Inc.
Eyenuk Inc. is a global artificial intelligence (AI) medical technology company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.
